A major weapon against cancer
- The cancer immunotherapy market for checkpoint inhibitors will increase to nearly $9 billion across the world’s major pharmaceutical markets in 2022.
- News of the successes of immunotherapies dominated the 2014 ASCO meeting.
- Immune approaches to cancer therapy have been validated by the recent approval of drugs such as Yervoy® and Provenge®.
- New immune modulators such as Anti PD-1 Keytruda®/PD-L1 mAb’s that boost T-cell activity in response to tumors are high priority development programs for Big Pharma.
- Analysts estimate that cancer immunotherapies could account for $35 billion annually within 10 years
The Susavion advantage
- Current therapies with monoclonal antibodies attack a single target and are very costly to produce. Side effects are significant but manageable.
- Susavion’s multivalent technology engages strategic targets on multiple cell types, instead of one, and activates key immune cells.
- Susavion’s platform drugs are produced synthetically, are relatively inexpensive, stable, and easily distributed world-wide.
- Susavion’s drugs have broad application against cancers, low toxicity, and thus are potentially game changes.